On July 16, 2025, HC Wainwright & Co., represented by analyst Yi Chen, reiterated its "Buy" rating for AngioDynamics (ANGO, Financial), maintaining the stock's price target at USD 16.00. This confirmation comes as the firm continues to view the stock with a positive outlook.
The previous and current price target for AngioDynamics (ANGO, Financial) remains stable at USD 16.00, with no percentage change. The rating reiteration signifies the firm's consistent belief in the company's potential, as reflected in the maintained price target and "Buy" rating.
Investors should note that the recommitment to the price target and rating by HC Wainwright & Co. underscores steady confidence in AngioDynamics (ANGO, Financial), supporting its standing in the market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for AngioDynamics Inc (ANGO, Financial) is $15.67 with a high estimate of $16.00 and a low estimate of $15.00. The average target implies an upside of 81.12% from the current price of $8.65. More detailed estimate data can be found on the AngioDynamics Inc (ANGO) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, AngioDynamics Inc's (ANGO, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for AngioDynamics Inc (ANGO, Financial) in one year is $8.26, suggesting a downside of 4.51% from the current price of $8.65. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the AngioDynamics Inc (ANGO) Summary page.
